Bright Minds Biosciences Inc. - common stock — États financiers (NASDAQ:DRUG)

Afficher le graphique complet Full chart

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

DRUG

Financials

Bright Minds Biosciences Inc. - common stock

Nouvelles

Piper Sandler relève l’objectif de cours de Bright Minds après des avancées

Jefferies initie la couverture de Bright Minds avec un achat sur le médicament antiépileptique

BTIG réitère sa note sur Bright Minds Biosciences en raison du potentiel du traitement des crises

H.C. Wainwright relève l’objectif de cours de Bright Minds à 145$ sur la base de données d’essais

Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data

Bright Minds Biosciences clôture son offre publique de 175 millions €

Bright Minds Biosciences clôture une offre publique de 175 millions €

Bright Minds Biosciences closes $175 million public offering

Bright Minds Biosciences fixe le prix de son offre publique à 90$ par action

Bright Minds Biosciences prices public offering at $90 per share

Bright Minds Biosciences fixe le prix de son offre publique à 175 millions $

Bright Minds Biosciences prices $175 million public offering